Research Paper Volume 13, Issue 2 pp 2264—2278

Figure 5. Silencing LINC00482 inhibits inflammation and angiogenesis through down-regulation of MMP-15 by targeting FOXA1. (A) The interference efficiency of MMP15 confirmed by RT-qPCR after treatment of sh-MMP15, * p < 0.05 vs. cells treated with sh-NC; (B) The interference efficiency of MMP15 confirmed by RT-qPCR after treatment of oe-LINC00482 + oe-FOXA1 + sh-MMP15, * p < 0.05 vs. cells treated with oe-LINC00482 + oe-FOXA1 + sh-NC; (C) Expression levels of TNF-α, IL-1β, IL-6 tested by ELISA, * p < 0.05 vs. cells treated with sh-NC, # p < 0.05 vs. cells treated with oe-LINC00482 + oe-FOXA1 + sh-NC; (D) The tube formation ability after treatment of sh-MMP15, oe-LINC00482 or oe-FOXA1 in each group, * p < 0.05 vs. cells treated with sh-NC, # p < 0.05 vs. cells treated with oe-LINC00482 + oe-FOXA1 + sh-NC; (E) Expressions of VEGF and NF-κB detected by Western blot analysis, * p < 0.05 vs. cells treated with sh-NC, # p < 0.05 vs. cells treated with oe-LINC00482 + oe-FOXA1 + sh-NC. The measurement data were presented as mean ± standard deviations. The differences between two groups were compared by unpaired t test. Experiments were repeated three times.